Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026
COVID-19 vaccine uptake, barriers and facilitators among key populations living with HIV/AIDS in Rivers State, Nigeria: a cross-sectional quantitative study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Korfii Uebari, Owhonda Golden, Kanee Rogers Bariture, Wali Ihuoma Aaron, Showers Viome Amakuro, Aigbogun Eric, Neenwi Mueka Edna, Akpona Dennis, Ajaero Ngozi, Ade-Dosumu Adedamola, Sanusi Fauwzia, Bashorun Damilola, Uchechukwu Etukokwu Ijeoma
Аннотация
BACKGROUND: The study evaluated COVID-19 vaccine uptake and the barriers and facilitators influencing COVID-19 vaccine uptake among key populations living with HIV/AIDS in Rivers State, Nigeria.
METHODS: A key population-based cross-sectional study employed purposive sampling to recruit 458 participants from one-stop shops between April-June 2024. Data collection tools were integrated into a Kobo database. SPSS version 27 (IBM, Armonk, USA) for descriptive and inferential statistics (Chi-square and bivariate logistic regression) analysed vaccine uptake and associated factors, with significance determined at p<0.05.
RESULTS: The COVID-19 vaccine uptake was 54.1%, with 22.3% partially vaccinated and 31.8% fully vaccinated. Pfizer-BioNTech (43.5%) and Moderna (22.2%) were the most administered vaccines. Key barriers included lack of information (91.7%), vaccine side effects concerns (88.0%), and distrust in vaccine safety (95.2%). Younger participants, those with shorter antiretroviral therapy (ART) durations, single individuals, and unemployed participants showed significantly lower vaccine uptake (χ²=48.266, 37.689, 29.131, and 62.136; p<0.001).
CONCLUSIONS: Moderate vaccine uptake highlights gaps in COVID-19 vaccination among key populations. To improve vaccine uptake, tailored interventions addressing stigma, misinformation, and access barriers are recommended. Leveraging community leaders and integrating vaccines into HIV/AIDS care programs can enhance acceptance and delivery.
METHODS: A key population-based cross-sectional study employed purposive sampling to recruit 458 participants from one-stop shops between April-June 2024. Data collection tools were integrated into a Kobo database. SPSS version 27 (IBM, Armonk, USA) for descriptive and inferential statistics (Chi-square and bivariate logistic regression) analysed vaccine uptake and associated factors, with significance determined at p<0.05.
RESULTS: The COVID-19 vaccine uptake was 54.1%, with 22.3% partially vaccinated and 31.8% fully vaccinated. Pfizer-BioNTech (43.5%) and Moderna (22.2%) were the most administered vaccines. Key barriers included lack of information (91.7%), vaccine side effects concerns (88.0%), and distrust in vaccine safety (95.2%). Younger participants, those with shorter antiretroviral therapy (ART) durations, single individuals, and unemployed participants showed significantly lower vaccine uptake (χ²=48.266, 37.689, 29.131, and 62.136; p<0.001).
CONCLUSIONS: Moderate vaccine uptake highlights gaps in COVID-19 vaccination among key populations. To improve vaccine uptake, tailored interventions addressing stigma, misinformation, and access barriers are recommended. Leveraging community leaders and integrating vaccines into HIV/AIDS care programs can enhance acceptance and delivery.